Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $34.9 million.

  • Keros Therapeutics' Share-based Compensation fell 54.79% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year decrease of 7.29%. This contributed to the annual value of $34.9 million for FY2024, which is 21.24% up from last year.
  • As of FY2024, Keros Therapeutics' Share-based Compensation stood at $34.9 million, which was up 21.24% from $28.8 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Share-based Compensation ranged from a high of $34.9 million in FY2024 and a low of $4.1 million during FY2020.
  • In the last 3 years, Keros Therapeutics' Share-based Compensation had a median value of $28.8 million in 2023 and averaged $27.4 million.
  • Data for Keros Therapeutics' Share-based Compensation shows a peak YoY spiked of 6,844.07% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Keros Therapeutics' Share-based Compensation stood at $4.1 million in 2020, then soared by 186.11% to $11.7 million in 2021, then soared by 59.38% to $18.7 million in 2022, then soared by 53.96% to $28.8 million in 2023, then grew by 21.24% to $34.9 million in 2024.